Discussion and dialogue drive change
We are always open to your questions
- Cannabis Agency visits DEMECANs production facilityDr. Constantin von der Groeben, Managing Director and co-founder of DEMECAN: “We are delighted that the cannabis agency has visited our premisesproduction facility. […]
- DEMECAN acquires Europe’s largest production facility for medical cannabis from WaylandDEMECAN, der pharmazeutische Produzent und Großhändler von medizinischem Cannabis verkauft ausgewählte Produkte ab sofort online im eigenen Onlineshop. […] (only german)
- Neuer Webshop für Apotheken: DEMECAN startet Online-Vertrieb von medizinischem CannabisDEMECAN, der pharmazeutische Produzent und Großhändler von medizinischem Cannabis verkauft ausgewählte Produkte ab sofort online im eigenen Onlineshop. […] (only german)
- DEMECAN secures additional fundingDEMECAN – the German specialist for medical cannabis – has raised a […]
- COVID-19 restrictions impact the global supply chain: DEMECAN imports medicinal cannabis from the Netherlands to ensure supply.The German medicinal drug market is currently experiencing exceptional circumstances due to the global COVID-19 pandemic. Supply chain […]
- DEMECAN signs binding supply agreement with Australia-based medical cannabis producerDEMECAN announces the signing of a three-year supply agreement with […]
- DEMECAN receives approval for the distribution of cannabis flowers from the NetherlandsDEMECAN is pleased to announce receipt of AmRadV approval from […]
- btov and Single Family Office Invest in German Cannabis: 7 Million Euros for DEMECANThe btov Private Investor Network and a German Single Family […]
- DEMECAN Confirms Award for German Medical Cannabis ProductionBERLIN, May 27, 2019 DEMECAN Holding GmbH [“DEMECAN” or “The […]
WE ARE OPEN TO PRESS INQUIRIES
Only discussion and dialogue drive change. We are happy to receive your questions regarding our company, medical cannabis and the possibilities of phytopharmacological research.
If you are looking for an interview partner covering these topics, please contact us.